Medigen Biotechnology Corp. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced sales was TWD 154.125 million compared to TWD 110.441 million a year ago. Operating loss was TWD 251.711 million compared to TWD 173.666 million a year ago. Net loss was TWD 110.625 million compared to TWD 86.738 million a year ago. Basic loss per share was TWD 0.79 compared to TWD 0.63 a year ago. For the nine months, sales was TWD 425.486 million compared to TWD 382.934 million a year ago. Operating loss was TWD 628.669 million compared to TWD 533.742 million a year ago. Net loss was TWD 271.394 million compared to TWD 114.845 million a year ago. Basic loss per share from continuing operations was TWD 1.95 compared to TWD 1.36 a year ago. Basic loss per share was TWD 1.95 compared to TWD 0.83 a year ago.